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Highlights 1 
 Texture features are dependent on the segmentation method  2 
 Prognostic scores differ between models derived using different segmentation methods 3 
 Patient risk stratification using identical clinical data is dependent on the segmentation 4 
method 5 
  6 
 3 
 1 
Background. 2 
Prognosis in oesophageal cancer (OC) is poor. The 5-year overall survival (OS) rate 3 
is approximately 15%. Personalised medicine is hoped to increase the 5 and 10-year 4 
OS rates. Quantitative analysis of PET is gaining substantial interest in prognostic 5 
research, but requires the accurate definition of the metabolic tumour volume. This 6 
study compares prognostic models developed in the same patient cohort using 7 
individual PET segmentation algorithms and assesses the impact on patient risk 8 
stratification. 9 
 10 
Methods. 11 
Consecutive patients (n=427) with biopsy-proven OC were included in final analysis. 12 
All patients were staged with PET/CT between September 2010 and July 2016. Nine 13 
automatic PET segmentation methods were studied. All tumour contours were 14 
subjectively analysed for accuracy and segmentation methods with <90% accuracy 15 
were excluded. Standardised image features were calculated and a series of 16 
prognostic models were developed using identical clinical data. The proportion of 17 
patients changing risk classification group were calculated. 18 
  19 
Results.  20 
Out of 9 PET segmentation methods studied, Clustering Means (KM2), General 21 
Clustering Means (GCM3), Adaptive Thresholding (AT) and Watershed Thresholding 22 
(WT) methods were included for analysis. Known clinical prognostic factors (age, 23 
treatment and staging) were significant in all of the developed prognostic models. AT 24 
and KM2 segmentation methods developed identical prognostic models. Patient risk 25 
stratification was dependent on the segmentation method used to develop the 26 
prognostic model with up to 73 patients (17.1%) changing risk stratification group. 27 
 28 
Conclusion.  29 
Prognostic models incorporating quantitative image features are dependent on the 30 
method used to delineate the primary tumour. This has a subsequent effect on risk 31 
stratification, with patients changing groups depending on the image segmentation 32 
method used.  33 
 4 
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 5 
Introduction 1 
Prognosis in oesophageal cancer (OC) is poor. The 1- and 5-year overall survival 2 
(OS) rate is 44% and 15%, respectively [1]. The aim of precision medicine and 3 
prognostic models is to ensure each patient is managed with the most appropriate 4 
treatment, which may improve patient OS [2–4]. The avoidance of futile aggressive 5 
therapies prevents unnecessary treatment and improves quality of life. In addition, 6 
better patient stratification may also allow more efficient trial designs. 7 
 8 
Prognostic models are formulated from patient specific information such as age, 9 
pathological subtype, molecular characterisation and tumour staging. However, the 10 
advanced quantitative analysis of medical images, especially CT, MR and PET, is 11 
gaining substantial interest in prognostic research as more accurate prognostic 12 
models may be developed. Radiomic features characterise tumour phentotypes 13 
through extraction of high dimensional data [5] and can be associated with 14 
metastatic growth, recurrence and survival in several solid cancers [6]. These 15 
methods may also have added prognostic value in cancer staging pathways [7]. 16 
 17 
The accurate delineation of the relevant metabolic tumour volume (MTV) on PET/CT 18 
is challenging due to low spatial resolution and the high noise characteristics of PET 19 
imaging [8]. Many different PET segmentation techniques have been proposed as a 20 
solution to the delineation of the MTV [9]. Numerous PET based radiomic features 21 
have been described, but the results of radiomic analysis are highly dependent on 22 
the method used to derive the MTV [10]. Few studies have compared results of 23 
radiomic analysis derived from each segmentation method (cf. [11] and references 24 
therein) or have investigated their effect on patient risk stratification derived from 25 
prognostic models [12–14].  26 
 27 
This study aimed to develop a series of prognostic models in the same patient cohort 28 
using identical clinical data and standardised radiomic features derived from different 29 
segmentation methods. The impact of using different segmentation methods on 30 
patient risk stratification was assessed.  31 
  32 
 33 
 34 
 6 
Materials and Methods 1 
 2 
Patient Cohort 3 
This is a retrospective cohort study of consecutive patients with biopsy-proven OC, 4 
including gastro-oesophageal junctional (GOJ) tumours, radiologically staged 5 
between 16th September 2010 and 31st July 2016. Patients were identified from a 6 
database of OC patients used in a previous study [15]. Institutional Review Board 7 
approval was granted and requirement for informed consent was waived (Wales 8 
REC 1, UK reference 14/WA/1208). 9 
 10 
Overall, 486 patients with FDG-avid primary oesophageal and GOJ tumours were 11 
considered for inclusion. Fourteen patients were excluded due to missing clinical 12 
data. All patients were deemed to have potentially curable disease following 13 
contrast-enhanced CT staging investigation. All PET/CT examinations were 14 
performed separately, following the initial CT, and reported in the same centre by 15 
Consultant Radiologists with an interest in Nuclear Medicine. Radiological staging 16 
was performed according to the International Union Against Cancer (UICC) TNM 7th 17 
edition [16]. Following exclusions, 472 patients were studied. 18 
 19 
PET/CT protocol 20 
Patients were fasted for at least 6 hours prior to tracer administration. Serum glucose 21 
levels were routinely checked and confirmed as less than 7.0 mmol/L prior to 22 
imaging. Patients received a dose of 4MBq of 18F-FDG/kg. Uptake time was 90 23 
minutes, standard practice at our institution. A GE 690 scanner (GE Healthcare, 24 
Buckinghamshire, UK) was used. CT images were acquired in a helical acquisition 25 
with a pitch of 0.98 and tube rotation speed of 0.5 seconds. Tube output was 120 26 
kVp with output modulation between 20 and 200 mA. Matrix size for the CT 27 
acquisition was 512 x 512 pixels with a 50 cm field of view. No oral or intravenous 28 
contrast was administered. PET images were acquired at 3 minutes per field of view. 29 
The length of the axial field of view was 15.7 cm (skull base to mid-thigh). Images 30 
were reconstructed with the ordered subset expectation maximisation algorithm, with 31 
24 subsets and 2 iterations. Matrix size was 256 x 256 pixels, using the VUE Point™ 32 
time of flight algorithm. All PET based data was obtained using the same PET/CT 33 
scanner and reconstruction method with voxel dimensions of 2.73 x 2.73 x 3.27 mm. 34 
 7 
 1 
 2 
Treatment Protocols 3 
Patients began treatment 2-4 weeks after staging FDG PET/CT imaging. Patients 4 
either had endoscopic mucosal resection (EMR), surgery alone, neo-adjuvant 5 
chemotherapy (NACT) or neo-adjuvant chemoradiotherapy (NACRT) prior to 6 
surgery, definitive chemo-radiotherapy (dCRT) or palliative therapy. The optimum 7 
treatment strategy was decided by consensus at the MDT. In general, fit patients 8 
with tumours pre-operatively staged as T3/T4a, N0/N1 were pre-operatively treated 9 
with NACT or NACRT. Less fit patients, or those with T1/2 N0 disease, had surgery 10 
alone. Patients deemed unsuitable for surgery due to co-morbidity and/or 11 
performance status, extensive loco-regional disease, or personal choice received 12 
dCRT. 13 
 14 
Data Preparation and PET Segmentation 15 
Manual delineation of the metabolic tumour volume (MTV) is limited by intra and inter 16 
observer variability and is time consuming [17–19]. Semi-automated and automated 17 
segmentation methods are favourable alternatives by reducing variability in 18 
delineation and decreasing the contouring time [20]. Fixed percentage thresholding 19 
has been shown to be dependent upon the SUVmax of a tumour as well as the MTV 20 
[21]. Furthermore, it has been shown that texture analysis of PET imaging is 21 
dependent upon the segmentation method used to define the MTV [12,22,23]. 22 
However, more complex segmentation algorithms such as adaptive iterative 23 
thresholding (AT) have been shown to be independent of SUVmax as well as being 24 
correlated to the MTV. Segmentation methods adopting clustering techniques such 25 
as Fuzzy C-means (FCM), Gaussian Fuzzy C-means (GCM) and K-means (KM) 26 
using 2,3 and 4 clusters (FCM2, GCM3 - 4, KM2 - KM4), as well as region growing 27 
(RG) and watershed transform (WT) methods, are promising segmentation methods 28 
in the delineation of the MTV. These segmentation methods are reviewed in detail in 29 
the report by Hatt et al [9], are described in detail previously [24] and are 30 
summarised in Table 1. In each case, the MTV was defined using AT, FCM2, GCM3, 31 
GCM4, KM2, KM3, KM4, RG and WT PET segmentation methods. 32 
 33 
 8 
Table 1: Name and description of PET-AS methods used in this study, with references of 1 
published work using similar segmentation approaches 2 
Algorithm Description Key References 
AT 
3D Adaptive iterative 
thresholding, using 
background subtraction 
 
Jentzen et al [25], Drever et al [26] 
RG 
3D Region-growing with 
automatic seed finder and 
stopping criterion 
 
Day et al [27] 
KM 
3D K-mean iterative 
clustering with custom 
stopping criterion 
 
Zaidi and El Naqa [8] 
FCM 
3D Fuzzy C-mean iterative 
clustering with custom 
stopping criterion 
 
Belhassen and Zaidi [28] 
GCM 
3D Gaussian Mixture 
Models based clustering 
with custom stopping 
criterion 
 
Hatt et al [29] 
WT 
Watershed Transform-
based algorithm, using 
sobel filter 
Geets et al [30], Tylski et al [31] 
 3 
A clinical radiologist subjectively assessed each tumour contour produced by all 9 4 
PET segmentation methods for accurate tumour representation. All tumour contours 5 
were visualised using the same software and image settings to ensure consistent 6 
methodology. Segmentation methods were considered inadequate for further 7 
analysis if less than 90% of contours were non-representative. This pre-defined 8 
value was decided upon prior to image visualisation. Contours were assessed 9 
individually and classified as not representative if contours were greatly different 10 
from the primary tumour, or included bone, lung or medistinial tissue. In addition, 11 
segmentation methods that had failed and conformed to the boundary of the 12 
bounding box were defined as not representative of the primary tumour. 13 
 14 
Clinical Data & image analysis 15 
 9 
Only primary tumours were analysed to ensure consistent methodology across all 1 
patients. Before quantitative image analysis and texture feature extraction, PET 2 
images were re-sampled into 0.5 SUV bins. A fixed bin width maintains a constant 3 
intensity resolution when compared to approaches based on fixed number of bins 4 
[32]. In the development of the prognostic models, age at diagnosis (number of 5 
years), radiological stage (stage IA-IV) and treatment (curative vs palliative) were 6 
included because these are strong predictors of survival [33]. Curative and palliative 7 
treatments were coded as 1 and 2 respectively. Radiological staging was modelled 8 
categorically. 9 
 10 
Radiomic analysis was performed using features implemented as part of the Image 11 
Biomarker Standardisation Initiative (IBSI), a multicenter, international collaboration 12 
aimed at improving the reproducibility and validation of quantitative medical image 13 
analysis studies [5]. The radiomic features selected for inclusion in this study were 14 
chosen as they have shown prognostic and predictive significance in other radiomic 15 
studies investigating OC [12,34,35]. These have been summarised in Table 2. 16 
Moreover, many radiomic feature implementations have been described [6,7,34,36] 17 
and are divided into three groups for which a summary is provided. In this study the 18 
MTV was analysed as a 3D volume with no thresholding applied to the MTV mask. 19 
 20 
Table 2: Summary of quantitative imaging features 21 
Type / Order of 
statistics 
Feature Brief Definition  
Morphological Volume 
 
Sum of voxels delineated multiplied by the volume of one 
voxel  
Pre-discretisation SUVmax 
 
Maximum uptake of FDG in the MTV 
 Energy 
 
Sum squared SUV values in the MTV 
First order  Skewness 
 
Measures symmetry of intensity histogram 
 Kurtosis 
 
Measures flatness of intensity histogram 
 Entropy 
 
Measures randomness  
 10 
Second order  Dissimilarity 
 
Variation of grey level pairs (GLCM). Features were 
calculated for each unique direction and averaged with a 
distance setting of 1. 
 
Higher order  Grey-level Non-uniformity 
 
Distribution of zone counts for each intensity value (GLSZM) 
 Zone Percentage 
 
Fraction of recorded zones compared to maximum possible 
 Coarseness Measures spatial rate of change in intensity using a distance 
of 1. 
 1 
First Order metrics 2 
First order statistical metrics summarise the voxel intensity distribution within the 3 
segmented MTV, without concern for spatial relationships[37]. First order metrics are 4 
typically histogram based and reduce the MTV to singular values describing the 5 
mean, minimum, maximum, median, uniformity of the intensities within the MTV. 6 
Included in first order stastical analysis is Skewness (asymmetry measure), Kurtosis 7 
(pointiness measure) and Entropy (randomness measure). Kurtosis and skewness 8 
have been shown to be independent predictors of survival [15], and of prognostic 9 
significance in the literature [38]. 10 
  11 
Higher Order metrics 12 
Higher order statistical metrics retain spatial information and are used to quantify 13 
inter-voxel intensity relationships. Dissimilarity is the quantification of variation in 14 
voxel pairs and is calculated using a Grey Level Co-occurrence Matrix (GLCM) 15 
generated for each unique direction and averaged. A low dissimilarity is resultant of 16 
neighboring voxels having similar values [39]. Zone percentage is calculated from a 17 
Grey Level Size Zone matrix (GLSZM) by assessing the fraction of recorded zones 18 
compared to the maximum number of possible zones. Heterogeneous MTV’s have 19 
high zone percentage scores. Grey Level Non-Uniformity (GLNU) is an evaluation of 20 
the distribution of zone counts for each intensity value. The feature value is low when 21 
the number of zones associated with each intensity value are similar. Coarseness is 22 
a neighborhood grey-tone difference matrix (NGTDM) feature that gives an indication 23 
of the level of spatial rate of change in intensity [40]. GLCM, GLSZM, NGTDM can 24 
be computed in 2D or 3D. The matrices in this study were computed in 3D as this 25 
may highlight the multi-scale, directional properties of tumour tissue [41]. 26 
 11 
 1 
Outcome Data 2 
The primary outcome of the study was OS, defined as number of months survived 3 
from date of diagnosis. Patients were followed-up 3-monthly for the first year, 6-4 
monthly until 5 years then annually thereafter, or until death. All included patients 5 
were followed-up for at least 12 months. Date of death was obtained from the 6 
Cancer Network Information System Cymru database (CaNISC, Velindre NHS Trust, 7 
Wales). 8 
 9 
Statistical Analysis 10 
Categorical variables were described as frequency (percent) and continuous 11 
variables as median (range) and differences assessed with appropriate non-12 
parametric tests. Cumulative survival was calculated by the Kaplan-Meier life-table 13 
method. Cox Regression models with backward conditional method were 14 
constructed using identical clinical data and imaging data derived from each of the 15 
segmentation methods. An individual prognostic score was calculated from each 16 
segmentation method by summation of the products of variables and their 17 
corresponding parameter estimate. Using this score, patients were separated into 18 
low, intermediate and high-risk groups (higher prognostic score deemed higher risk) 19 
and a log-rank test evaluated significant differences in OS. The number of patients 20 
that changed risk stratification group depending on the segmentation method used 21 
was calculated, and the OS for the different risk groups between models was 22 
analysed. A p-value of < 0.05 was considered statistically significant. Statistical 23 
analysis was performed using SAS version 9.4 (SAS, North Carolina, USA) and 24 
SPSS version 23.0 (IBM, Chicago, USA). Imaging data, software and delineated 25 
MTV’s are not available publicly. 26 
 27 
Results 28 
Four hundred and seventy-two patients, each with 9 MTV contours delineated by AT, 29 
FCM2, GCM3, GCM4, KM2, KM3, KM4, RG and WT PET segmentation methods 30 
were assessed by a Clinical Radiologist with five-years research experience for 31 
accurate tumour representation. Forty-five patients and 5 segmentation methods 32 
were excluded due to poor MTV delineation. FCM2 failed to delineate an acceptable 33 
 12 
tumour representation in 145 (30.8%) of cases. KM3 and KM4 failed in 88 (18.6%) 1 
and 215 (45.6%) of cases, respectively. RG failed in 389 (82.5%), and GCM4 in 33 2 
(7%) of cases. Therefore, 427 cases with MTV’s delineated with KM2, GCM3, AT 3 
and WT PET segmentation methods deemed to have accurate tumour 4 
representation and included for further analysis.  5 
 6 
The 427 cases included for analysis were used to develop the prognostic models for 7 
KM2, WT, GCM3 and AT methods. Baseline characteristics of patients are detailed 8 
in Table 3. The median OS of the cohort was 17.0 months (95% confidence interval 9 
(95% CI) 14.8-19.2). Median follow-up was 35.0 months (95% CI 28.7-41.3). Overall 10 
1- and 2-year survival in the development cohort was 65.3% and 30.1%, 11 
respectively. 12 
 13 
 14 
Table 3: Baseline characteristics of patient cohort 15 
Median age 67.0 year (range 24-84) 
Gender Male 315 (73.8): Female 112 (26.2) 
Histology 
Adenocarcinoma 
Squamous Cell Carcinoma 
Undifferentiated 
High-grade Dysplasia 
Neuro-endocrine 
Small Cell Carcinoma 
Sarcoma 
 
313 (73.3) 
100 (23.4) 
5 (1.2) 
4 (0.9) 
3 (0.7) 
1 (0.2) 
1 (0.2) 
Tumour Location 
Oesophagus 
Upper third 
Middle third 
Lower Third 
Gastro-oesophageal junction 
Siewert I 
Siewert II 
 
268 (62.8) 
14 (5.2) 
71 (26.5) 
183 (68.3) 
159 (37.2) 
67 (42.1) 
42 (26.4) 
 13 
Siewert III 50 (31.4) 
Stage Group 
IA 
IB 
IIA 
IIB 
IIIA 
IIIB 
IIIC 
IV 
 
10 (2.3) 
17 (4.0) 
70 (16.4) 
13 (3.0) 
97 (22.7) 
52 (12.2) 
76 (17.8) 
92 (21.5) 
Treatment 
Curative 
NACT 
dCRT 
Surgery Alone 
NACRT 
EMR 
Palliative 
 
224 (52.5) 
86 (38.4) 
86 (38.4) 
31 (13.8) 
20 (8.9) 
1 (0.5) 
203 (47.5) 
Mortality 
Alive 
Dead 
 
132 (30.9) 
295 (69.1) 
 1 
 2 
Development of Prognostic Models 3 
The final steps of each prognostic model are presented in Table 4. Three known 4 
clinical prognostic factors (age, radiological stage and treatment) remained in each 5 
derived model, but there was a difference in the inclusion of texture metrics by 6 
segmentation technique. AT and KM2 produced the same model output. 7 
Interestingly, IBSI metrics were not included in the final models for these 8 
segmentation methods. However, skewness and kurtosis were independently 9 
significant for survival using GCM3 method. Skewness and GLNU were significant 10 
using WT method. Their inclusion in the models illustrates their additional prognostic 11 
value compared with current prognostic factors. 12 
 14 
 1 
Table 4: Final Output of Prognostic Models Derived Using AT, GCM3, KM2 and WT PET 2 
Segmentation Methods 3 
AT Parameter 
Estimate 
p-value Hazard Ratio 95% CI 
Age 0.020 0.001 1.020 1.008 – 1.033 
Treatment -1.075 <0.001 0.341 0.254 – 0.459 
Stage 0.144 <0.001 1.155 1.072 – 1.245 
     
GCM3 Parameter 
Estimate 
p-value Hazard Ratio 95% CI 
Age 0.019 0.003 1.019 1.006 – 1.032 
Treatment -1.024 <0.001 0.359 0.266 – 0.485 
Stage 0.142 <0.001 1.153 1.068 – 1.245 
Kurtosis 0.632 0.002 1.882 1.260 – 2.809 
Skewness -0.789 0.044 0.454 0.211 – 0.980 
     
KM2 Parameter 
Estimate 
p-value Hazard Ratio 95% CI 
Age 0.020 0.001 1.020 1.008 – 1.033 
Treatment -1.075 <0.001 0.341 0.254 – 0.459 
Stage 0.144 <0.001 1.155 1.072 – 1.245 
     
WT Parameter 
Estimate 
p-value Hazard Ratio 95% CI 
Age 0.018 0.004 1.018 1.006 – 1.031 
Treatment -1.063 <0.001 0.345 0.257 – 0.464 
Stage 0.140 <0.001 1.150 1.065 – 1.242 
GLNU 0.017 0.006 1.017 1.005 – 1.029 
Skewness 0.674 0.030 1.962 1.067 – 3.607 
     
 4 
 5 
 15 
Prognostic Score Calculation 1 
The equations for each model derived from different segmentation methods were 2 
used to calculate the prognostic scores, and are listed in Table 5. These calculations 3 
were derived using published methods [42]. 4 
 5 
Table 5: Prognostic model equations 6 
Segmentation 
Method 
Prognostic Model Equation 
AT (Age * 0.020) - (Treatment * 1.075) + (Stage * 0.144) 
 
GCM3 (Age * 0.019) - (Treatment * 1.024) + (Stage * 0.142) - (Skewness 
* 0.789) + (Kurtosis * 0.632) 
 
KM2 (Age * 0.020) - (Treatment * 1.075) + (Stage * 0.144) 
 
WT (Age * 0.018) - (Treatment * 1.063) + (Stage * 0.140) + 
(Skewness * 0.674) + (GLNU * 0.017) 
 
 7 
 8 
Figure 1 shows the risk stratification for WT, KM2, AT, and GCM3. Median OS for 9 
the low risk, intermediate risk and high-risk group in the AT and KM2 derived 10 
prognostic model was 36.0 months (29.9-42.1 months), 18.0 months (15.1-20.9 11 
months) and 9.0 months (7.8-10.2 months) respectively. Median OS for the low risk, 12 
intermediate risk and high-risk group in the GCM3 derived prognostic model was 13 
36.0 months (28.8 - 43.2 months), 18.0 months (15.4 - 20.6 months) and 9.0 months 14 
(7.7-19.2 months). Median OS for the WT derived prognostic model low risk, 15 
intermediate and high-risk groups was 36 months (27.8-44.2 months), 19 months 16 
(15.1-23 months) and OS for the high-risk group was 9 months (7.7-10.3 months) 17 
respectively. Table 6 shows the number of patients stratified as low, intermediate 18 
and high risk for each single prognostic model along with the prognostic score range 19 
for each risk stratification group. Table 7 shows the number of patients whom 20 
change risk stratification.  21 
 16 
 1 
The largest proportion of patients to change risk stratification group was between 2 
prognostic models based on GCM3 and on WT (n=73, 17.1%). It can be noted that 3 
no patient changed risk stratification group between AT and KM2 because the 4 
prognostic models were identical. The number of concordant patients stratified as 5 
low, intermediate and high-risk across the developed models was 118 (28%), 95 6 
(22%) and 116 (27%) respectively. There was no overall survival difference between 7 
AT, GCM3, KM2 or WT low-risk groups (X2 0.052, df 3, p=0.997), intermediate-risk 8 
groups (X2 0.016, df 3, p=0.999) or high-risk groups (X2 0.028, df 3, p=0.999). 9 
 10 
For interest, supplementary data A describes the developed prognostic models for 11 
the excluded PET-AS methods. Supplementary data B describes variances in 12 
radiomic features extracted using differing discretisation methodologies, which is an 13 
important consideration in radiomic studies. Supplementary data C describes the 14 
correlation of MTV with the extracted radiomic features. 15 
 16 
Table 6: Number of patients in each risk stratification group for each single prognostic model 17 
and prognostic score range 18 
number of 
patients in 
risk group 
(prognostic 
range) 
Low Risk 
Intermediate 
Risk 
High Risk 
AT/KM2 
 
141  
(-0.45 – 0.98) 
 
143 
 (0.99 – 2.16) 
143  
(2.17 – 2.79) 
GCM3 
 
140 
(-1.13 – 0.36) 
 
143 
(0.37 – 1.54) 
144  
(1.55 – 2.73) 
 17 
WT 
142 
(-0.17 – 1.30) 
 
144 
(1.31 – 2.48) 
 
 
141 
(2.49-3.62) 
 
    
 1 
2 
Figure 1: Risk stratification and OS for WT (Top Left), KM2 (Top Right), AT (Bottom Left), GCM3 (Bottom Right). 
 18 
 1 
Table 7: Total number of patients and percentage that change risk-stratification group 2 
Number 
changing 
group 
(%) 
AT GCM3 KM2 WT 
AT 
 
 
 
 
   
GCM3 
 
66 
(15.4) 
 
   
KM2 
 
0 
(0.0) 
 
 
66 
(15.4) 
 
  
WT 
57 
(13.3) 
 
73 
(17.1) 
 
 
57 
(13.3) 
 
 
 
 
 3 
 4 
Discussion 5 
Radiomic research aims to improve the prediction of patient outcome through the 6 
extraction of additional data from medical images. However, numerous challenges with 7 
the extraction of radiomic features have been highlighted [10]. Selection of significant 8 
features for prognostic models is of considerable importance because external 9 
parameters such as delineation method and image reconstruction parameters affect 10 
reproducibility and robustness of these features [14,43]. 11 
 19 
 1 
In this study, first, second and higher-order radiomic features were extracted from each 2 
of the PET-AS delineations. The significant variables in the developed prognostic 3 
models were dependent upon the delineation method. In the GCM3 based prognostic 4 
models, first-order features Kurtosis and Skewness were found to be significant 5 
predictors of survival. However, higher-order feature GLNU was found to be of 6 
significance in combination with the first-order feature Skewness in the WT based 7 
prognostic model. For the AT and KM2 based prognostic models, radiomic features 8 
were not found to be significant predictors of survival in comparison to the currently 9 
known predictors such as clinical stage and age. This highlights the dependency of 10 
significant PET radiomic variables on segmentation method.  11 
 12 
Our findings demonstrate the potential impact of different segmentation methods for 13 
prognostic models using standardised implementations of radiomic features within 14 
clinical practice. Patients may be assigned different risk stratification groups depending 15 
on the segmentation method used in the process of developing the prognostic model. 16 
This could lead to sub-groups of patients receiving a more aggressive treatment than is 17 
necessary, leading to decreased quality of life. Furthermore, patients could potentially 18 
be denied beneficial treatment. 19 
 20 
Nine segmentation methods were included in this study, with 5 being excluded from 21 
analysis after being reviewed by a radiologist. These methods were excluded due to 22 
poor tumour representation in a number of cases. In supplementary data A, the 23 
prognostic models developed from PET-AS methods that were excluded from the study 24 
are described. Interestingly, the excluded PET-AS methods FCM2, KM3, KM4 and RG 25 
developed identical prognostic models to the included methods AT and KM2. This 26 
suggests that whilst radiomic features are dependent upon the delineation method, this 27 
may be unrelated to the delineation method considered acceptable by a radiologist.  28 
 29 
It has been reported that the accuracy of the segmentation delineation of the MTV is 30 
dependent upon tumour characteristics [9,21,24]. GCM based segmentation methods 31 
 20 
have been shown to have limited performance in low TBR scenarios [24]. Furthermore, 1 
clustering methods such as FCM are highly dependent upon the heterogeneity of the 2 
tumour volumes. In homogeneous regions with low TBR’s the iterative process of FCM 3 
has been shown to overestimate the tumour volume [29]. Statistical based 4 
segmentation algorithms such as RG compare adjoining voxel intensities. If the voxels 5 
are of similar intensities they are included within the volume [44]. However, the 6 
performance of statistical based RG segmentation algorithms in highly heterogeneous 7 
tumour volumes is degraded. Moreover, the performance of RG is dependent upon the 8 
defined stopping criteria. In our study, the RG algorithm stopped voxel inclusion when 9 
after an iteration no more than 5% of the total number of voxels already defined as the 10 
MTV were included. This stopping criteria has been reported to be limited in complex 11 
tumours [24].  12 
 13 
This study used radiomic data derived using SUV bins of 0.5 units. In supplementary 14 
data B, the variance of radiomic features derived using different discretisation methods 15 
is shown but lies outside the scope of this study, so further analysis was not performed. 16 
Future work could investigate how different discretisation methods influences the 17 
significance of radiomic features in the development of prognostic models and 18 
subsequent impact on risk stratification in patients with OC. 19 
 20 
The variability in segmentation performance in any one single clinical case means the 21 
standardisation of the delineation of the MTV is critical for the application of radiomics 22 
within OC. This supports the recommendations of the International Atomic Energy 23 
Agency (IAEA) whom state that there are no validated quantitative approaches for PET 24 
contouring that will result in ideal tumor delineation for all patients and tumor locations 25 
[45]. In addition, the American Association of Physicist in Medicine (AAPM) Task Group 26 
No 211 reported could not recommend a single PET auto segmentation method for 27 
MTV delineation. However, machine learned segmentation methods have showed 28 
promise for accurate MTV delineation [9]. Machine learned based and consensus based 29 
segmentation methodologies have been proposed for the standardisation of the 30 
delineation of the MTV [20,46,47]. In supplementary data C, radiomic features derived 31 
 21 
from each segmentation method were correlated with MTV. As described, GLNU, 1 
Energy and Coarseness were correlated with MTV for all PET segmentation methods. 2 
However, the level of correlation varied between PET-AS methods. Our study suggests 3 
that a standardised segmentation methodology should be used for the development of 4 
prognostic models. 5 
 6 
Shape metrics can also be quantified from the primary tumour. Within this group of 7 
radiomic features, the surface to volume ratio (S2VR), sphere to volume ratio, 8 
compactness, sphericity and disproportion of the tumour can be characterised but have 9 
not been included in this study which focused on intra-tumoural heterogeneity. 10 
However, studies have investigated the inclusion of shape metrics in prognostic models 11 
[48]. 12 
 13 
The results of this study are strengthened by the large cohort (n=427) of OC patients 14 
with contours assessed and approved by a clinical radiologist. The approach of 15 
controlling model development by using identical clinical data and standardised image 16 
features ensured that differences in risk stratification were due to the image 17 
segmentation method. In this study, we did not use any PET image interpolation 18 
algorithm before image feature analysis [41]. This approach however, is consistent with 19 
currently reported studies. 20 
 21 
Conclusion 22 
Prognostic models incorporating quantitative image features are dependent on the 23 
method used to delineate the primary tumour. This has a subsequent effect on risk 24 
stratification, with patients changing groups depending on the image segmentation 25 
method used. The standardisation of PET segmentation is important and should be 26 
considered in future prognostic and predictive clinical models. The findings of this study 27 
may have substantial potential impact on clinical management of patients with OC. 28 
  29 
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